# A Study of Mezigdomide in Healthy Participants and Participants With Hepatic Impairment

> **NCT05707390** · PHASE1 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 32 (actual)

## Conditions studied

- Hepatic Impairment

## Interventions

- **DRUG:** Mezigdomide

## Key facts

- **NCT ID:** NCT05707390
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-02-20
- **Primary completion:** 2023-09-13
- **Final completion:** 2023-09-13
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2024-02-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05707390

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05707390, "A Study of Mezigdomide in Healthy Participants and Participants With Hepatic Impairment". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05707390. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*